Abbott Laboratories vs Arbutus Biopharma Corp · latest fiscal year · computed from SEC XBRL filings
| Metric | ABT | ABUS |
|---|---|---|
| Revenue | $44.33B | $14.1M |
| Revenue growth (YoY) | 5.7% | 128.2% |
| Operating margin | 18.2% | -271.0% |
| Net margin | 14.7% | -237.9% |
| FCF margin | 16.7% | -281.5% |
| Capex % of revenue | 4.9% | 0.0% |
Want ABT against its full peer set, not just ABUS?
The CompsDesk pack: up to 12 peers you choose, up to 14 metrics (6 core guaranteed), trends for every filed year (up to five), a citation on every number — board-ready PDF + CSV, $249.
Green = better on that metric where direction is unambiguous. Source: SEC EDGAR XBRL (10-K). "n/a" = not disclosed under mapped tags; never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.